Bausch + Lomb provides financial details for planned acquisition of Novartis eye-care assets

Bausch Health Companies Inc.

Deal: $1.75B upfront plus up to $750M milestones for Xiidra, AcuStream, SAF312, OJL332.
Acquired assets generated $487M net revenue in 2022 and $468M in 2021.
Acquisition expected to close at or around end of September 2023, subject to conditions.
Audited and unaudited abbreviated financial statements of acquired assets furnished as exhibits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.